Photo of Maryam Asgari,  MD, MPH

Maryam Asgari, MD, MPH

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 762-0149


MASGARI@PARTNERS.ORG

Maryam Asgari, MD, MPH

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Dermatology, Harvard Medical School
  • Associate Professor, Population Medicine, Harvard Medical School
  • Director, High Risk Skin Cancer Clinic, Dermatology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Maryam Asgari is a board-certified dermatologist, epidemiologist, and Mohs micrographic surgeon who specializes in the care of patients with skin cancer. Dr. Asgari's area of excellence is Investigation with a focus on epidemiology of skin diseases. Her research has focused on pharmacoepidemiology and skin cancer risk, interactions of immunity and skin cancer, high risk skin cancer, and patient-centered outcomes including patient satisfaction in skin cancer treatment. She is also known for her clinical expertise in procedural dermatology.

Dr. Asgari is also recognized as a clinical expert in Mohs surgery. She has served as an ad hoc reviewer for major journals including the American Journal of Epidemiology, Cancer Epidemiology, Biomarkers & Prevention, Dermatologic Surgery, JAMA Dermatology, Journal of the American Academy of Dermatology and Journal of Investigative Dermatology. She has also held national leadership positions in the Society of Investigative Dermatology and the American Academy of Dermatology. Within the American Academy of Dermatology, she was elected to serve as a member of the prestigious Melanoma and Skin Cancer Committee, which helps to establish guidelines for skin cancer care. She also served as an indication reviewer to help establish national guidelines for the Appropriate Use Criteria for Mohs surgery.

Publications

Powered by Harvard Catalyst
  • Gilkey MB, Mays D, Asgari MM, Kornides ML, McRee AL. Parental Support for Age-based Indoor Tanning Restrictions. Am J Prev Med 2017. PubMed
  • Asgari MM, Ray GT, Quesenberry CP, Katz KA, Silverberg MJ. Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load. JAMA Dermatol 2017; 153:892-896. PubMed
  • Wehner MR, Levandoski KA, Kulldorff M, Asgari MM. Research Techniques Made Simple: An Introduction to¬†Use and Analysis of Big Data in Dermatology. J Invest Dermatol 2017; 137:e153-e158. PubMed
  • Asgari MM, Chien AJ, Tsai AL, Fireman B, Quesenberry CP. Association between lithium use and melanoma risk and mortality: A population-based study. J Invest Dermatol 2017. PubMed
  • Storer M, Zhu Z, Sokil M, Ford M, Neugebauer R, Asgari MM. Community-Based Practice Variations in Topical Treatment of Actinic Keratoses. JAMA Dermatol 2017. PubMed
  • Levandoski KA, Nazarian RM, Asgari MM. Hypertrophic lichen planus mimicking squamous cell carcinoma: The importance of clinicopathologic correlation. JAAD Case Rep 2017; 3:151-154. PubMed
  • Yesantharao P, Wang W, Ioannidis NM, Demehri S, Whitemore AS, Asgari MM. Cutaneous Squamous Cell Cancer (cSCC) Risk and the Human Leukocyte Antigen (HLA) System. Hum Immunol 2017. PubMed
  • Asgari MM, Ray GT, Geier JL, Quesenberry CP. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol 2017. PubMed
  • Moshiri AS, Doumani R, Yelistratova L, Blom A, Lachance K, Shinohara MM, Delaney M, Chang O, McArdle S, Thomas H, Asgari MM, Huang ML, Schwartz SM, Nghiem P. Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. J Invest Dermatol 2016. PubMed
  • Asgari MM. Utility and Limitations of Large Population-Based Data for Skin Cancer Outcomes. J Invest Dermatol 2016; 136:2128-2130. PubMed
  • Albrecht J, Lebwohl M, Asgari MM, Bennett DD, Cook A, Evans CC, Green LJ, Hodge JA, Kourosh AS, Maloney ME, Howard LM, Olsen EA, Rosenberg SP, Rubin A, Stough DB, Taylor SC, Brod BA. The state and consequences of dermatology drug prices in the United States. J Am Acad Dermatol 2016; 75:603-5. PubMed
  • Asgari MM, Toland AE, Arron ST. IRF4 polymorphism is associated with cutaneous squamous cell carcinoma in organ transplant recipients: a pigment-independent phenomenon. J Invest Dermatol 2016. PubMed
  • Ray GT, Kulldorff M, Asgari MM. Geographic Clusters of Basal Cell Carcinoma in a Northern California Health Plan Population. JAMA Dermatol 2016. PubMed
  • Iyer JG, Parvathaneni K, Bhatia S, Tarabadkar ES, Blom A, Doumani R, McKenzie J, Asgari MM, Nghiem P. Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. J Am Acad Dermatol 2016. PubMed
  • Asgari MM, Wang W, Ioannidis NM, Itnyre J, Hoffmann T, Jorgenson E, Whittemore AS. Identification of Susceptibility Loci for Cutaneous Squamous Cell Carcinoma. J Invest Dermatol 2016; 136:930-7. PubMed
  • Moore MM, Geller AC, Warton EM, Schwalbe J, Asgari MM. Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011. J Am Acad Dermatol 2015; 73:630-6. PubMed
  • Jiang AJ, Eide MJ, Alexander GL, Altschuler A, Asgari MM, Geller AC, Fletcher SW, Halpern AC, Weinstock MA. Providers' Experiences with a Melanoma Web-Based Course: a Discussion on Barriers and Intentions. J Cancer Educ 2015. PubMed
  • Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012. JAMA Dermatol 2015. PubMed
  • Asgari MM, Arron ST, Warton EM, Quesenberry CP, Weisshaar D. Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant¬†recipients (SOTRs). J Am Acad Dermatol 2015. PubMed
  • Asgari MM, Warton EM, Whittemore AS. Family history of skin cancer is associated with increased risk of cutaneous squamous cell carcinoma. Dermatol Surg 2015; 41:481-6. PubMed
  • Hoffmann TJ, Sakoda LC, Shen L, Jorgenson E, Habel LA, Liu J, Kvale MN, Asgari MM, Banda Y, Corley D, Kushi LH, Quesenberry CP, Schaefer C, Van Den Eeden SK, Risch N, Witte JS. Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort. PLoS Genet. 2015; 11:e1004930. PubMed
  • Paulson KG, Iyer JG, Simonson WT, Blom A, Thibodeau RM, Schmidt M, Pietromonaco S, Sokil M, Warton EM, Asgari MM, Nghiem P. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. Am J Clin Pathol 2014; 142:452-8. PubMed
  • Asgari MM, Warton EM, Quesenberry CP, Koralek DO, Taylor M. Risk of subsequent cutaneous squamous cell carcinoma in patients with melanoma. J Am Acad Dermatol 2014; 71:521-8. PubMed
  • Asgari MM, Eide MJ, Warton M, Fletcher SW. Comparing characteristics of melanoma cases arising in health maintenance organizations with state and national registries. Melanoma Res 2014; 24:381-7. PubMed
  • Asgari MM, Sokil MM, Warton EM, Iyer J, Paulson KG, Nghiem P. Effect of host, tumor, diagnostic, and treatment variables on outcomes in a large cohort with Merkel cell carcinoma. JAMA Dermatol 2014; 150:716-23. PubMed
  • Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, Herrinton LJ. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug Saf 2013; 22:842-9. PubMed
  • Asgari MM, Eide MJ, Warton EM, Fletcher SW. Validation of a large basal cell carcinoma registry. J Registry Manag 2013; 40:65-9. PubMed
Hide